---

Type II Alveolar Epithelial Cell (AT2 Cell / Type II Pneumocyte)

---

1. Overview and Nomenclature

• Also called: type II pneumocyte, granular pneumocyte, great alveolar cell, septal cell
• Classically termed the "defender of the alveolus" (Mason & Williams, 1977)
• Despite being called the "large alveolar cell," its mean volume is actually less than half that of the type I cell (Table 2-2, Fishman's)
• Numerically the more abundant cell type, but covers only ~5% of the alveolar surface (type I cells cover ~95%)

---

2. Morphology and Ultrastructure

• Cuboidal shape; apical surface bulges into the alveolar lumen
• Located preferentially at alveolar corners and near pores of Kohn
• Usually found as solitary cells; clustering occurs only during repair after injury

• Microvilli on apical surface (concentrated at periphery, smooth center)
• Abundant cytoplasmic organelles: mitochondria, rough ER with ribosomes, well-developed Golgi complex
• Multivesicular bodies (MVBs): junction point between biosynthetic and endocytic pathways
• Lamellar bodies: the hallmark organelle (see below)
• Basement membrane beneath AT2 cells is occasionally interrupted - foot processes can extend into interstitium toward interstitial cells
• Forms junctions (tight junctions + desmosomes) with adjacent type I cells

---

3. Lamellar Bodies - The Defining Organelle

---

4. Surfactant - Synthesis, Secretion, and Recycling

Composition

• ~90% lipids: mainly saturated phosphatidylcholine (DPPC)
• ~10% proteins: SP-A, SP-B, SP-C, SP-D
• Motto: "Keeps alveoli open, dry, and clean"

Surfactant Proteins and Their Roles

Intra-alveolar Surfactant Subtypes (in sequence)

1. Freshly secreted lamellar body-like forms (hypophase)
2. Tubular myelin - unique lattice structure, probable precursor of surface film (SP-A + SP-B required)
3. Surface film - reduces alveolar surface tension
4. Small unilamellar vesicles - "spent" surfactant for recycling

Secretion Mechanism

• Lamellar body membrane fuses with apical plasma membrane
• Fusion pore forms, diameter < lamellar body diameter
• Surfactant is squeezed through the pore
• Primary physiologic trigger: mechanical stretch during ventilation (direct on AT2 cells, or indirectly via AT1 cells/capillary endothelium as "strain sensors")

Clearance and Recycling

• Major route: Reuptake by type II cells → recycled or degraded
• Minor routes: Alveolar macrophage ingestion + lysosomal degradation; clearance via airways
• SP-A inhibits secretion and stimulates reuptake (negative feedback)

---

5. Functions of the Type II Cell - "Defender of the Alveolus"

A. Surfactant Production

1. Prevents alveolar atelectasis - surface area-dependent reduction of alveolar surface tension
2. Prevents intra-alveolar edema - reduces transcapillary fluid forces
3. Innate host defense - immunomodulatory functions (especially SP-A and SP-D)

B. Alveolar Epithelial Regeneration (Stem Cell Role)

• AT2 cells are progenitor/stem cells of the alveolar epithelium
• Can transdifferentiate into type I alveolar cells (AT1) after injury
• Normally found singly; proliferates to form clusters during epithelial repair
• AT2 progenitor cells reside in niches adjacent to fibroblasts
• Wnt signaling (juxtacrine, from fibroblasts) maintains the AT2 stem cell pool
• Autocrine Wnt activation in AT2 cells prevents transdifferentiation to AT1
• Blockade of Wnt in AT2 → permits AT1 transdifferentiation (in vitro)
• Demonstrated using "alveolospheres" - organoid assays in Matrigel with fibroblasts

---

6. Pathological Significance

Surfactant Dysfunction Disorders

ER Stress and UPR in Fibrosis

• SP-A2 and SP-C mutations → misfolded surfactant proteins → ER stress → Unfolded Protein Response (UPR)
• AT2 dysfunction: acquires profibrotic phenotype → promotes fibroblast expansion, myofibroblast activation, ECM deposition
• AT2 cells do not directly transform into mesenchymal cells (no EMT)
• In IPF: loss of AT2 cells + expansion of basal cells documented by single-cell RNA sequencing

AT2 in IPF (Fishman's, block 11)

• AT2 cells have reduced regenerative capacity in IPF organoid assays
• Restoration of AT2 regenerative capacity = active therapeutic target
• Expanded basal cells in IPF produce secretory-primed phenotype in mucin-rich areas

---

7. Key Distinguishing Features vs. Type I Cell

---

8. Surfactant Replacement Therapy (Clinical Correlate)

• Primary indication: RDS of premature neonates
• One of the major advances in neonatology
• Expanding indications: other forms of respiratory failure (ARDS) where endogenous surfactant is impaired/inactivated
• Efficacy depends on preparation's ability to resist the same inhibition that inactivated the endogenous system
• The story of surfactant therapy is a paradigmatic example of translational bench-to-bedside medicine

---

Sources: Fishman's Pulmonary Diseases and Disorders, 5e (Chapter 2 - Alveolar Architecture; Chapter on IPF) | Murray & Nadel's Textbook of Respiratory Medicine, 7e